The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Arcus Biosciences Inc | COM | 03969F109 | 24,410 | 3,070,423 | SH | OTR | 1,2,3 | 0 | 3,070,423 | 0 | |
| Arcus Biosciences Inc | COM | 03969F109 | 3,740 | 470,427 | SH | OTR | 3 | 0 | 470,427 | 0 | |
| Constellation Pharmceticls I | COM | 210373106 | 31,374 | 2,554,850 | SH | OTR | 3 | 0 | 2,554,850 | 0 | |
| Constellation Pharmceticls I | COM | 210373106 | 26,072 | 2,123,089 | SH | OTR | 3 | 0 | 2,123,089 | 0 | |
| Gritstone Oncology Inc | COM | 39868T105 | 34,567 | 3,102,934 | SH | OTR | 1,2,3 | 0 | 3,102,934 | 0 | |
| NGM Biopharmaceuticals Inc | COM | 62921N105 | 33,171 | 2,265,758 | SH | OTR | 1,2,3 | 0 | 2,265,758 | 0 | |
| NGM Biopharmaceuticals Inc | COM | 62921N105 | 165,481 | 11,303,333 | SH | OTR | 3 | 0 | 11,303,333 | 0 | |
| NGM Biopharmaceuticals Inc | COM | 62921N105 | 31,110 | 2,125,000 | SH | OTR | 3 | 0 | 2,125,000 | 0 | |